Kailera Therapeutics, Inc. Common Stock (KLRA)vsRegeneron Pharmaceuticals Inc (REGN)
KLRA
Kailera Therapeutics, Inc. Common Stock
$22.88
-2.55%
HEALTHCARE · Cap: $2.45B
REGN
Regeneron Pharmaceuticals Inc
$612.50
+0.42%
HEALTHCARE · Cap: $64.47B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
KLRA
Avoid22
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KLRA.
Margin of Safety
+54.7%
Fair Value
$1346.63
Current Price
$612.50
$734.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : KLRA
KLRA has a balanced fundamental profile.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : KLRA
The primary concerns for KLRA are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
KLRA profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (64/100 vs 22/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kailera Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kailera Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies for rare genetic diseases, leveraging advanced technologies to address unmet medical needs. The company's proprietary platform is designed to enhance the precision and effectiveness of therapeutic interventions, targeting various genetic disorders. By collaborating with leading research institutions and leveraging a robust intellectual property portfolio, Kailera aims to bring transformative treatments to patients and position itself as a leader in the gene therapy market. As it advances its product pipeline, Kailera is committed to delivering sustainable value to its investors and stakeholders.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?